Figure 5.

Absence of the CD57/NKG2C NK cell phenotype otherwise found in HCMV-EBV coinfection. NK cell subsets, including CD56^brightCD16^neg (1), CD56^brightCD16^pos (2), CD56^dimCD16^pos (3), and CD56^negCD16^pos (4), were evaluated for each group of children: Nandi (EBV^low/malaria^low), Kisumu (EBV^high/malaria^high), and eBL patients with no/low EBV and high EBV loads. (A) Comparison of CD57 among the different NK cell subsets across study groups. (B) CD57 expression on the CD56^negCD16^pos NK cell subset across study groups. (C) Comparison of NKG2C expression among different NK cell subsets across groups of children. (D) NKG2C expression on the CD56^negCD16^pos NK cell subset across study groups. (E) Median fluorescence intensity (MFI) of antibody titers against CMV. (F) Coexpression of CD57 and NKG2C on CD56^dimCD16^pos and CD56^negCD16^pos NK cells. (G) CD57^posNKG2C^pos expression between CD56^dimCD16^pos and CD56^negCD16^pos subsets across study groups. For CD57, Nandi, n = 8; Kisumu, n = 6, and BL, n = 11. For NKG2C, Nandi, n = 7; Kisumu, n = 5; and BL, n = 11. Data are mean ± SD. *P < .05, **P < .01, ***P < .001.